Inadequately Controlled Type-II Diabetes Treatment Market Report 2025

The inadequately controlled type II diabetes treatment market size has grown strongly in recent years. It will grow from $18.5 billion in 2024 to $20.09 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth during the historic period is attributed to the increasing prevalence of type II diabetes, the expanding geriatric population, the rise in obesity and sedentary lifestyles, growing awareness of diabetes management, and greater investment in diabetes research.

The inadequately controlled type II diabetes treatment market size is expected to see strong growth in the next few years. It will grow to $25.57 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth during the forecast period is driven by the wider adoption of novel diabetes therapies, rising demand for peptide- and cell-based treatments, the expansion of healthcare infrastructure in emerging markets, the increase in clinical trials for innovative diabetes drugs, and stronger government support for chronic disease management. Key trends in the forecast period include advancements in personalized diabetes treatments, progress in drug delivery technologies, development of dual-action peptide therapies, innovation in minimally invasive treatment methods, and advancements in combination therapy approaches.

The growing use of digital health technologies is contributing to the expansion of the inadequately controlled type-II diabetes treatment market. Digital health solutions involve the application of digital tools to enhance healthcare delivery, improve outcomes, and support effective health management. Their adoption is increasing due to the convenience of remote access to care, which strengthens patient involvement and improves treatment efficiency. In the context of managing inadequately controlled type-II diabetes, these solutions allow for continuous monitoring of blood glucose levels, tracking of medication adherence, and personalized guidance on lifestyle and treatment choices, all aimed at improving blood sugar control. For example, in April 2025, the American Hospital Association, a nonprofit organization based in the United States, reported that in 2022, 86.9 percent of hospitals offered telehealth services, up from 86 percent in 2021, showing consistent growth in the use of digital healthcare. This trend is helping to drive the growth of the market focused on treating inadequately controlled type-II diabetes.

Leading companies in the inadequately controlled type-II diabetes treatment market are developing new treatment methods, including peptide-based therapies, to improve blood sugar regulation and reduce complications associated with type-II diabetes. These therapies are designed to mimic or enhance the action of natural peptides that influence blood glucose, thereby increasing insulin sensitivity and supporting better glucose control. In May 2022, Eli Lilly and Company, a pharmaceutical firm based in the United States, received approval from the United States Food and Drug Administration for Mounjaro, a tripeptide injection intended to improve blood sugar levels in adults with type-II diabetes, alongside diet and exercise. Tirzepatide, the active ingredient in the treatment, is a dual-acting weekly injection that targets two key hormones involved in blood sugar regulation glucagon-related peptide one and glucose-dependent insulinotropic polypeptide. The first helps stimulate insulin production and reduce glucagon, while the second also supports insulin secretion. Tirzepatide represents a promising option for patients whose condition has not been adequately managed with previous treatments.

In September 2023, Abbott Laboratories, a healthcare company based in the United States, acquired Bigfoot Biomedical Inc. for an undisclosed amount. The goal of this acquisition is to expand Abbott’s diabetes care offerings by combining Bigfoot Biomedical’s advanced insulin management systems with Abbott’s FreeStyle Libre continuous glucose monitoring technology. This integration is intended to deliver more connected, individualized, and accurate diabetes management tools. Bigfoot Biomedical is a medical technology company in the United States focused on developing smart insulin delivery systems and digital tools for managing diabetes.

Major players in the inadequately controlled type-ii diabetes treatment market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Bayer AG, Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, GSK plc, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Biogen Inc., Incyte Corporation, Karyopharm Therapeutics, Zylig Lifesciences.

North America was the largest region in inadequately controlled type-II diabetes treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inadequately controlled type II diabetes treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the inadequately controlled type II diabetes treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Inadequately controlled type-II diabetes treatment refers to therapeutic approaches designed to regulate blood glucose levels in patients whose condition remains uncontrolled despite lifestyle changes and initial treatments. The goal is to lower hyperglycemia, prevent complications, and enhance overall quality of life by optimizing treatment strategies.

The primary types of inadequately controlled type-II diabetes treatment include oral medications, insulin therapy, lifestyle modifications, combination therapy, and alternative therapies. Oral medications are drugs taken in the form of tablets, capsules, or liquids to help control blood glucose in individuals with type-II diabetes. These cover various drug classes such as insulin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, thiazolidinediones, and others, administered through routes including oral, subcutaneous, intravenous, transdermal, and inhalation. Treatments are applied across patient groups such as adults, elderly individuals, and children, and are distributed through multiple channels including retail pharmacies, online pharmacies, hospitals and clinics, and direct-to-consumer services.

The inadequately controlled type-II diabetes treatment market research report is one of a series of new reports that provides inadequately controlled type-II diabetes treatment market statistics, including the inadequately controlled type-II diabetes treatment industry global market size, regional shares, competitors with the inadequately controlled type-II diabetes treatment market share, detailed inadequately controlled type-II diabetes treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the inadequately controlled type-II diabetes treatment industry. This inadequately controlled type-II diabetes treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The inadequately controlled type II diabetes treatment market consists of revenues earned by entities by providing services such as diabetes management programs, telemedicine, lifestyle counseling, and patient monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The inadequately controlled type II diabetes treatment market also includes sales of fixed-dose combination drugs, anti-obesity drugs, antihypertensive drugs, insulin pumps, and blood glucose meters. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.